Molecular Formula | C17H22N2O3 |
Molar Mass | 302.37 |
Density | 1.159±0.06 g/cm3(Predicted) |
Boling Point | 515.6±40.0 °C(Predicted) |
Solubility | DMSO: >10mg/mL |
Appearance | powder |
Color | white to off-white |
pKa | 14.19±0.46(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 6 months. |
In vitro study | CL-82198 (10 μM; 24 hours) significantly reduces LS174 cell migration. CL-82198 decreases CTGF and TGF-β1 protein levels in hepatic stellate cells. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 22 - Harmful if swallowed |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.307 ml | 16.536 ml | 33.072 ml |
5 mM | 0.661 ml | 3.307 ml | 6.614 ml |
10 mM | 0.331 ml | 1.654 ml | 3.307 ml |
5 mM | 0.066 ml | 0.331 ml | 0.661 ml |
biological activity | CL-82198 is a selective MMP-13 inhibitor. CL-82198 binds to the entire S1 'pocket of MMP-13, which is the basis of its lack of inhibitory activity against MMP-13 selectivity and other MMPs. CL-82198 available for osteoarthritis (OA) research. |
Animal Model: | 10-week-old C57BL/6J mice (performed MLI surgery) |
Dosage: | 1, 5, 10 mg/kg body weight |
Administration: | Intraperitoneal injection; every other day for 12 weeks |
Result: | Prevented and decelerated MLI-induced osteoarthritis progression. |